Background: Alzheimer's disease (AD) pathology can be quantified in vivo using
cerebrospinal fluid (CSF) levels of amyloid-1-42 (A1-42), total-tau (t-tau), and …

Background: Two approaches are available for measuring Alzheimer's disease (AD)
pathology in vivo. Biomarkers in cerebrospinal fluid (CSF) include amyloid-β 1-42 (Aβ 42) …

Background: Recently, a Korean research group suggested a consensus protocol, based on
the Alzheimer's Disease Neuroimaging Initiative study protocol but with modifications for …

Background: PET imaging using [18F] fluorodeoxyglucose (FDG) and [11C] Pittsburgh
compound B (PIB) have been proposed as biomarkers of Alzheimer disease (AD), as have …

Background: In mild cognitive impairment (MCI), Alzheimer's disease (AD)-type
cerebrospinal fluid (CSF) biomarker profiles predict rapid progression and conversion to AD …

BACKGROUND: The positron emission tomography (PET) tracer [11C]-Pittsburgh
Compound-B ([11C] PIB) allows the in vivo assessment of amyloid plaque burden in the …

The diagnostic performances of cerebrospinal fluid (CSF) biomarkers and amyloid positron
emission tomography (PET) were compared by examining the association and concordance …

Background: Tau positron emission tomography (PET) imaging is used in research, but its
relation to cerebrospinal fluid (CSF) tau and other Alzheimer's disease (AD)-related clinical …

Background: Cerebrospinal fluid (CSF) biomarker studies have shown variable accuracy for
diagnosis of Alzheimer's disease (AD); therefore, internal validation is recommended …

Introduction Measurement of amyloid beta (Aβ40 and Aβ42) and tau (phosphorylated tau [p‐
tau] and total tau [t‐tau]) in cerebrospinal fluid (CSF) can be utilized to differentiate clinical …